At a recent event organized by that consortium, the New Jersey Alliance for Clinical and Translational Science(NJACTS), leaders from academia, healthcare, government and the pharmaceutical industry discussed the future of scientific and clinical trial innovation in the state. These new innovations will result from a $33-million grant from the National Institutes of Health (NIH). To read the full story.
Recent Posts
- Rutgers Develops New Tool for Examining Cancer Genomic Data that Could Improve Treatment.
- New Jersey bans some products with toxic PFAS chemicals. Here’s what to know.
- How a Simple Dietary Change May Slow Liver Cancer in At-Risk Patients.
- Join NJ ACTS Clinical Research Management Collaborative Series on 3/31 from 12-1:30
- NJACTS Community Engagement Core COVID-19 Resources
Categories
- Community (2,451)
- Covid (998)
- CTO Events (6)
- News (3,105)
- Pilots (21)